Skip to main content
DongKookPharmaceuticalCo.,Ltd. logo

DongKookPharmaceuticalCo.,Ltd. — Investor Relations & Filings

Ticker · 086450 ISIN · KR7086450004 KO Manufacturing
Open in API
Filings indexed 159 across all filing types
Latest filing 2026-05-15 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 086450

About DongKookPharmaceuticalCo.,Ltd.

https://www.dkpharm.co.kr/en/

DongKook Pharmaceutical Co., Ltd. is a pharmaceutical company engaged in the research, development, manufacturing, and distribution of medical products. Established in 1968, the company focuses on improving human health and quality of life. Its product portfolio includes prescription and non-prescription drugs, with key therapeutic areas in anesthetics, contrast media, anti-cancer agents, antibiotics, and oral healthcare treatments. The company operates its own Active Pharmaceutical Ingredient (API) synthesis facilities and invests in research and development to create innovative therapeutic solutions. It provides both finished products and raw materials to domestic and international markets.

Recent filings

Filing Released Lang Actions
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 95% confidence The document is clearly titled “분기보고서 (제59기 1분기)” covering the period January 1, 2026 to March 31, 2026 and filed with the Financial Supervisory Service and Korea Exchange. It includes complete financial statements (summary financials, consolidated financials and notes), management’s discussion and analysis, auditor’s report, corporate overview, shareholding details, and other detailed sections typical of a statutory quarterly report in Korea. This is not a brief earnings release or an announcement that a report is published, but the full quarterly report itself. Therefore, it matches the definition of an Interim / Quarterly Report (IR). Q1 2026
2026-05-15 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 95% confidence The document is a formal regulatory filing submitted to the Financial Services Commission/Korea Exchange regarding the appointment of an outside director (사외이사). It details the appointment of a specific individual following a general meeting. This falls under the category of Board/Management Information (MANG) as it pertains to changes in the board of directors.
2026-03-20 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official report of the results of a General Meeting of Shareholders (AGM). It details the approval of financial statements, dividend resolutions, and the election of directors and auditors. This falls under the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it provides the outcome of the shareholder votes.
2026-03-20 Korean
사업보고서 (2025.12)
Audit Report / Information Classification · 100% confidence The document is a comprehensive 'Consolidated Audit Report' (연결감사보고서) for Dongkook Pharmaceutical Co., Ltd. It includes the independent auditor's report, consolidated financial statements (balance sheet, income statement, statement of changes in equity, cash flow statement), and detailed notes. It covers the fiscal year ending December 31, 2025. Since it contains the full audited financial statements and the auditor's opinion, it is classified as an Audit Report (AR). FY 2025
2026-03-12 Korean
감사보고서제출
Audit Report / Information Classification · 95% confidence The document is a formal regulatory filing titled '감사보고서 제출' (Submission of Audit Report) from Dongkook Pharmaceutical. It provides a summary of the audit opinion (unqualified/appropriate), key financial data (assets, liabilities, equity, revenue, profit), and details regarding the auditor (Samjong Accounting Corp). While it contains financial data, it is a structured regulatory disclosure summarizing the audit results rather than the full annual report or a standalone audit report document. Given the specific nature of the disclosure regarding audit outcomes and financial summaries, it fits the 'Audit Report / Information' category. FY 2025
2026-03-12 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Dongkook Pharmaceutical's 58th Annual General Meeting. It contains the meeting agenda, voting procedures (including electronic voting), and management reference materials (business overview, board activities, and financial highlights). This document is a standard proxy statement/notice sent to shareholders to inform them of the upcoming meeting and solicit their votes, which falls under the 'Proxy Solicitation & Information Statement' category.
2026-03-05 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.